Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial-Reference-Cited by-同舟云学术

Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial

Published:2013-09 Issue:3 Volume:59 Page:536-542
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Wong Vincent Wai-Sun,Chan Ruth Suk-Mei,Wong Grace Lai-Hung,Cheung Bernice Ho-Ki,Chu Winnie Chiu-Wing,Yeung David Ka-Wai,Chim Angel Mei-Ling,Lai Jennifer Wing-Yan,Li Liz Sin,Sea Mandy Man-Mei,Chan Francis Ka-Leung,Sung Joseph Jao-Yiu,Woo Jean,Chan Henry Lik-Yuen

Publisher

Elsevier BV

Subject

Hepatology

Reference27 articles.

1. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study;Williams;Gastroenterology,2011

2. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography;Wong;Gut,2012

3. The natural history of nonalcoholic fatty liver disease: a population-based cohort study;Adams;Gastroenterology,2005

4. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years;Wong;Gut,2010

5. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis;Ascha;Hepatology,2010

Cited by 269 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic dysfunction-associated steatotic liver disease and diabetes: the cross-talk between hepatologist and diabetologist;Expert Review of Gastroenterology & Hepatology;2024-08-02

2. Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease;Clinics and Research in Hepatology and Gastroenterology;2024-08

3. Metabolic dysfunction associated fatty liver disease in healthy weight individuals;Hepatology International;2024-07-25

4. MASLD- Global prevalence, pathophysiological processes and management pathways- tackling a complex problem;Gastroenterology & Hepatology: Open access;2024-07-25

5. A roadmap for clinical trials in MASH-related compensated cirrhosis;Nature Reviews Gastroenterology & Hepatology;2024-07-17